Zacks Research Has Bearish Forecast for Omnicell Q3 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Zacks Research dropped their Q3 2026 earnings per share estimates for Omnicell in a research report issued to clients and investors on Thursday, February 26th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.25 per share for the quarter, down from their previous estimate of $0.29. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2026 earnings at $0.28 EPS.

A number of other brokerages have also recently commented on OMCL. Benchmark upped their price target on Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 4th. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a research report on Wednesday, January 7th. Wall Street Zen downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Wells Fargo & Company increased their price objective on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $54.50.

Omnicell Stock Up 1.4%

Omnicell stock opened at $41.93 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. The firm has a 50 day moving average price of $45.16 and a 200-day moving average price of $37.85. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.00. The company has a market capitalization of $1.88 billion, a P/E ratio of 1,048.51, a P/E/G ratio of 1.45 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The business had revenue of $313.98 million for the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the sale, the executive vice president directly owned 91,674 shares of the company’s stock, valued at $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.52% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV increased its stake in shares of Omnicell by 51.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,573 shares of the company’s stock worth $615,000 after acquiring an additional 4,599 shares in the last quarter. State of Tennessee Department of Treasury boosted its position in shares of Omnicell by 15.1% during the fourth quarter. State of Tennessee Department of Treasury now owns 26,504 shares of the company’s stock valued at $1,285,000 after buying an additional 3,470 shares during the last quarter. EP Wealth Advisors LLC bought a new position in Omnicell during the 4th quarter valued at about $307,000. Fuller & Thaler Asset Management Inc. purchased a new stake in Omnicell in the fourth quarter worth approximately $610,000. Finally, Empowered Funds LLC bought a new position in shares of Omnicell in the 4th quarter worth approximately $274,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.